Resverlogix Corp.



Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.

March 4, 2016: Coroprate Update Webcast. Please access webcast here: 

On Sept. 25, 2015, Resverlogix’s clinical and scientific teams along with Professor Kausik K. Ray and Dr. Kamyar Kalantar-Zadeh of the BETonMACE clinical steering committee presented a Research & Development Update for apabetalone (RVX-208) in New York City. The archived event can be accessed here:

Events - Q2 2016

Resverlogix will be attending several key industry conferences. Website will be udated as presentation opportunities become available. Please note: not all events offer a presentation opportunity and this list is subject to change.

April 2-4: ACC.16 Scientific Sessions, Chicago, IL. 

April 4-6: BIO Europe Spring, Stockholm, Sweden. Presenting on April 5.

April 28: New York Academy of Science, Epigenetics: Cancer and Beyond. Session chair and presenter.

May 2-3: Bloom Burton & Co. Healthcare Investor Conference, Toronto, ON. Presenting on May 2.

May 2-4: BioNetwork East, Orlando, FL. Presenting on May 2.

May 5-7: ATVB/PVD, Nashville, TN.

May 21-24: ERA/EDTA, Vienna, Austria. 

May 29-June 1: EAS 2016, Innsbruck, Austria. 

June 6-9: BIO International Convention, San Francisco, CA. 

June 10-14: ADA Scientific Sessions, New Orleans, LA. 

Resverlogix in the Media

March 29: CTV news filmed on location the RVX lab featuring the Sanofi Biogenius competition

Jan. 20, 2016: Resverlogix featured in the Life Sciences Report

Sept. 2015: At the 2015 Rodman & Renshaw healthcase conference, Don McCaffrey had a video interview with Stock News Now (SNN).

Aug. 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.”

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. 

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam.

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. 

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. 

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M.

To arrange a media interview, please contact Sarah Zapotichny, Director of Investor Relations & Corporate Communications at